Our simulation indicates that suppression of Treg expansion with IL-2 antibody and blockade of PC-Treg and PC-TAM interactions appear to re-activate anti-tumor immune responses and to prevent CRPC occurrence. The gene discussed is IL2; the disease is neoplasm.